

World Journal of *Experimental Medicine*

Quarterly Volume 14 Number 3 September 20, 2024



EDITORIAL

Khosla D, Singh PK, Chhabria BA, Kataria V, Singh N, Kapoor R. Malignant pleural mesothelioma: The disdained member of thoracic oncology! *World J Exp Med* 2024; 14(3): 91739 [DOI: [10.5493/wjem.v14.i3.91739](https://doi.org/10.5493/wjem.v14.i3.91739)]

OPINION REVIEW

Kokudeva M, Vichev M, Naseva E, Miteva DG, Velikova T. Artificial intelligence as a tool in drug discovery and development. *World J Exp Med* 2024; 14(3): 96042 [DOI: [10.5493/wjem.v14.i3.96042](https://doi.org/10.5493/wjem.v14.i3.96042)]

REVIEW

English KJ. Anal carcinoma - exploring the epidemiology, risk factors, pathophysiology, diagnosis, and treatment. *World J Exp Med* 2024; 14(3): 98525 [DOI: [10.5493/wjem.v14.i3.98525](https://doi.org/10.5493/wjem.v14.i3.98525)]

MINIREVIEWS

Rai P, Garain T, Gupta D. Phytochemical analysis of *Tinospora cordifolia* and *Withania somnifera* and their therapeutic activities with special reference to COVID-19. *World J Exp Med* 2024; 14(3): 95512 [DOI: [10.5493/wjem.v14.i3.95512](https://doi.org/10.5493/wjem.v14.i3.95512)]

Rahmati M, Moghtaderi H, Mohammadi S, Al-Harrasi A. Aryl hydrocarbon receptor dynamics in esophageal squamous cell carcinoma: From immune modulation to therapeutic opportunities. *World J Exp Med* 2024; 14(3): 96269 [DOI: [10.5493/wjem.v14.i3.96269](https://doi.org/10.5493/wjem.v14.i3.96269)]

El Assaad N, Chebly A, Salame R, Achkar R, Bou Atme N, Akouch K, Rafoul P, Hanna C, Abou Zeid S, Ghosn M, Khalil C. Anti-aging based on stem cell therapy: A scoping review. *World J Exp Med* 2024; 14(3): 97233 [DOI: [10.5493/wjem.v14.i3.97233](https://doi.org/10.5493/wjem.v14.i3.97233)]

ORIGINAL ARTICLE**Retrospective Study**

Patel B, Khadke S, Mahajan K, Dhingra A, Trivedi R, Brar SS, Dixit S, Periwal V, Chauhan S, Desai R. Association of cannabis use disorder with atrial fibrillation in young men without concomitant tobacco use: Insights from nationwide propensity matched analysis. *World J Exp Med* 2024; 14(3): 93742 [DOI: [10.5493/wjem.v14.i3.93742](https://doi.org/10.5493/wjem.v14.i3.93742)]

Viswas A, Dabla PK, Shrivastav D, Gupta S, Yadav M, Yadav S, Koner BC. SCN1A rs6732655A/T polymorphism: Diagnostic and therapeutic insights for drug-resistant epilepsy. *World J Exp Med* 2024; 14(3): 94999 [DOI: [10.5493/wjem.v14.i3.94999](https://doi.org/10.5493/wjem.v14.i3.94999)]

Chaiwisitkun A, Muengtawepong S. Platelet-to-neutrophil ratio predicts hemorrhagic transformation and unfavorable outcomes in acute ischemic stroke with intravenous thrombolysis. *World J Exp Med* 2024; 14(3): 95540 [DOI: [10.5493/wjem.v14.i3.95540](https://doi.org/10.5493/wjem.v14.i3.95540)]

Clinical and Translational Research

Bangolo AI, Auda A, Bukasa-Kakamba J, Bhakta N, Dey S, Iilhoru A, Reddy G, Alqinai B, Sidiqui A, Sekhon I, Khatiashvili B, Abbas I, Kunnel S, Jarri A, Martinez E, Daoud D, Gupta I, Gompa H, Pender S, Aljaberi D, Aljanaahi H, Kunnel SS, Xiao Y, Jung Y, Nagpaul S, Naz A, Mallela T, Maung PM, Khalaf IY, Kim S, Alrestom R, Gajera A, Alkealy H, Kansal D, Dhall S, Satheesha S, Weissman S, Fwelo P. Interaction between tumor stage and age on survival outcomes of patients with anaplastic thyroid cancer. *World J Exp Med* 2024; 14(3): 93869 [DOI: 10.5493/wjem.v14.i3.93869]

Basic Study

Pierzynowska K, Wychowański P, Zaworski K, Woliński J, Donaldson J, Szkopek D, Roszkowicz-Ostrowska K, Kondej A, Pierzynowski SG. Amylase intrapancreatic infusion delays insulin release during an intravenous glucose tolerance test, proof of acini-islet-acinar interactions. *World J Exp Med* 2024; 14(3): 92589 [DOI: 10.5493/wjem.v14.i3.92589]

SYSTEMATIC REVIEWS

Amedu AN. Addressing trauma, post-traumatic stress disorder, and post-traumatic growth in breast cancer patients. *World J Exp Med* 2024; 14(3): 95565 [DOI: 10.5493/wjem.v14.i3.95565]

LETTER TO THE EDITOR

Gana N, Huluta I, Gica N. Hypoglycaemia in screening oral glucose tolerance test in pregnancy with low birth weight fetus. *World J Exp Med* 2024; 14(3): 96720 [DOI: 10.5493/wjem.v14.i3.96720]

ABOUT COVER

Peer Reviewer of *World Journal of Experimental Medicine*, Rachid AIT ADDI, MD, PhD, Epidemiologist-Anthropobiologist, Research Scientist, Laboratory Associate member of Human Ecology, Department of Biology, University of Cadi Ayyad Marrakesh, Morocco. dr.rachid.aitaddi@gmail.com.

AIMS AND SCOPE

The primary aim of the *World Journal of Experimental Medicine (WJEM, World J Exp Med)* is to provide scholars and readers from various fields of experimental medicine with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJEM mainly publishes articles reporting research results and findings obtained in the field of experimental medicine and covering a wide range of topics including clinical laboratory medicine (applied and basic research in hematology, body fluid examination, cytomorphology, genetic diagnosis of hematological disorders, thrombosis and hemostasis, and blood typing and transfusion), biochemical examination (applied and basic research in laboratory automation and information system, biochemical methodology, and biochemical diagnostics), etc.

INDEXING/ABSTRACTING

The *WJEM* is now abstracted and indexed in PubMed, PubMed Central, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The *WJEM*'s CiteScore for 2023 is 1.7 and Scopus CiteScore rank 2023: Internal medicine is 109/167.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Wen-Bo Wang*; Production Department Director: *Xu Guo*; Cover Editor: *Ji-Hong Liu*.

NAME OF JOURNAL

World Journal of Experimental Medicine

ISSN

ISSN 2220-315x (online)

LAUNCH DATE

December 20, 2011

FREQUENCY

Quarterly

EDITORS-IN-CHIEF

Jian Wu

EXECUTIVE ASSOCIATE EDITORS-IN-CHIEF

Fang Gong

EDITORIAL BOARD MEMBERS

<https://www.wjnet.com/2220-315x/editorialboard.htm>

PUBLICATION DATE

September 20, 2024

COPYRIGHT

© 2024 Baishideng Publishing Group Inc

PUBLISHING PARTNER

Department of Clinical Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital

INSTRUCTIONS TO AUTHORS

<https://www.wjnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjnet.com/bpg/gerinfo/208>

POLICY OF CO-AUTHORS

<https://www.wjnet.com/bpg/GerInfo/310>

ARTICLE PROCESSING CHARGE

<https://www.wjnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

PUBLISHING PARTNER'S OFFICIAL WEBSITE

<http://www.smh.cc/home2020/page/index/index.html>

Clinical and Translational Research

Interaction between tumor stage and age on survival outcomes of patients with anaplastic thyroid cancer

Ayrton I Bangolo, Auda Auda, John Bukasa-Kakamba, Nayan Bhakta, Shraboni Dey, Anupriya Iilhori, Gowry Reddy, Budoor Alqinai, Aman Siddiqui, Imranjot Sekhon, Barbare Khatiasvili, Iqra Abbas, Sandra Kunnel, Amer Jarri, Emelyn Martinez, Deborah Daoud, Ishita Gupta, Harshini Gompa, Silvanna Pender, Dana Aljaberi, Hamed Aljanaahi, Sandra S Kunnel, Yingxia Xiao, Yoontae Jung, Sneha Nagpaul, Afshan Naz, Tejaswee Mallela, Phyo Maung Maung, Ibtihal Y Khalaf, Soobee Kim, Roua Alrestom, Aditya Gajera, Hiba Alkealy, Deepti Kansal, Sonam Dhall, Sanya Satheesha, Simcha Weissman, Pierre Fwelo

Specialty type: Oncology**Provenance and peer review:**

Invited article; Externally peer reviewed.

Peer-review model: Single blind**Peer-review report's classification****Scientific Quality:** Grade B, Grade C**Novelty:** Grade B, Grade C**Creativity or Innovation:** Grade B, Grade C**Scientific Significance:** Grade B, Grade C**P-Reviewer:** Sahin TT; Ueda H**Received:** March 7, 2024**Revised:** June 13, 2024**Accepted:** June 25, 2024**Published online:** September 20, 2024**Processing time:** 175 Days and 2.1 Hours

Ayrton I Bangolo, Shraboni Dey, Budoor Alqinai, Aman Siddiqui, Imranjot Sekhon, Amer Jarri, Silvanna Pender, Sneha Nagpaul, Sanya Satheesha, Department of Internal Medicine, Palisades Medical Center, North Bergen, NJ 07047, United States

Auda Auda, Nayan Bhakta, Anupriya Iilhori, Gowry Reddy, Barbare Khatiasvili, Iqra Abbas, Sandra Kunnel, Emelyn Martinez, Deborah Daoud, Ishita Gupta, Harshini Gompa, Dana Aljaberi, Hamed Aljanaahi, Sandra S Kunnel, Yingxia Xiao, Yoontae Jung, Afshan Naz, Tejaswee Mallela, Phyo Maung Maung, Ibtihal Y Khalaf, Soobee Kim, Roua Alrestom, Aditya Gajera, Hiba Alkealy, Deepti Kansal, Sonam Dhall, Simcha Weissman, Department of Medicine, Palisades Medical Center, North Bergen, NJ 07047, United States

John Bukasa-Kakamba, Department of Endocrine and Metabolic Disorders, University of Kinshasa, Kinshasa Kinshasa, Congo

Pierre Fwelo, Department of Epidemiology, Human Genetics, and Environmental Sciences, UTHHealth School of Public Health, Houston, TX 77030, United States

Corresponding author: Ayrton I Bangolo, MBBS, MD, Doctor, Department of Internal Medicine, Palisades Medical Center, 7600 River Road, North Bergen, NJ 07047, United States. ayrtonbangolo@yahoo.com

Abstract**BACKGROUND**

Anaplastic thyroid cancer (ATC) is an aggressive, rare malignancy associated with rapid growth and metastasis, and a very poor prognosis. We investigated the clinical characteristics, survival outcomes and independent prognostic factors associated with anaplastic thyroid cancer.

AIM

To assess to what extent the interaction between age and tumor stage affects mortality.

METHODS

A total of 622 patients diagnosed with anaplastic thyroid cancer, between 2010 and 2017 were enrolled in our study by retrieving data from the Surveillance, Epidemiology and End Results (SEER) database. We analyzed demographics, clinical characteristics, overall mortality (OM) and cancer specific mortality (CSM) of ATC. Variables with a *P* value < 0.1 were incorporated into the multivariate cox model to determine the independent prognostic factors. Furthermore, we analyzed the interaction between age and tumor stage on mortality.

RESULTS

In the multivariate analyses, the divorced/separated population had a lower OM [hazard ratio (HR) = 0.63, 95%CI: 0.42-0.94, *P* < 0.05] and CSM (HR = 0.61, 95%CI: 0.40-0.92, *P* < 0.05). OM was higher in tumors with direct extension only (HR = 6.26, 95%CI: 1.29-30.42, *P* < 0.05) and tumors with distant spread (HR = 5.73, 95%CI: 1.34-24.51, *P* < 0.05). CSM was also higher in tumors with direct extension (HR = 5.05, 95%CI: 1.05-24.19, *P* < 0.05) and tumors with distant spread (HR = 4.57, 95%CI: 1.08-19.29, *P* < 0.05). Mortality was not adversely affected by lymph node involvement. OM was lower in patients who received radiation (HR = 0.66, 95%CI: 0.53-0.83, *P* < 0.01), chemotherapy (HR = 0.63, 95%CI: 0.50-0.79, *P* < 0.01) or surgery (HR = 0.53, 95%CI: 0.43-0.66, *P* < 0.01). CSM was also lower in patient who received radiation (HR = 0.64, 95%CI: 0.51-0.81, *P* < 0.01), chemotherapy (HR = 0.62, 95%CI: 0.50-0.78, *P* < 0.01) or surgery (HR = 0.51, 95%CI: 0.41-0.63, *P* < 0.01). There was no significant interaction between age and tumor stage that affected mortality.

CONCLUSION

In this large US SEER database retrospective study, we found the mortality to be higher in advanced stage tumors with direct extension and distant metastasis. However, patients who received aggressive therapy showed a better overall survival. The aim of our study is to emphasize the importance of detecting ATC at an early stage and provide aggressive therapy to these patients. Since advanced stage ATC is associated with a dismal prognosis, we emphasize the need for randomized control trials and development of novel therapies that will be used to treat ATC.

Key Words: Undifferentiated thyroid cancer; Survival outcome; Prognosis; Metastasis; Clinical trials; Interaction

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Anaplastic thyroid cancer (ATC) represents a rare and highly aggressive subtype of thyroid cancer. Due to its rarity, limited information exists regarding the survival outcomes of patients with ATC. This study aims to provide the most current and comprehensive analysis of survival outcomes among ATC patients, with a specific emphasis on the interaction between two independent prognostic factors. Our findings indicate higher mortality rates in cases of advanced-stage tumors with direct extension and distant metastasis. Nevertheless, patients who underwent aggressive therapy exhibited improved overall survival rates.

Citation: Bangolo AI, Auda A, Bukasa-Kakamba J, Bhakta N, Dey S, lilhori A, Reddy G, Alqinai B, Sidiqiu A, Sekhon I, Khataishvili B, Abbas I, Kunnel S, Jarri A, Martinez E, Daoud D, Gupta I, Gompa H, Pender S, Aljaberi D, Aljanaahi H, Kunnel SS, Xiao Y, Jung Y, Nagpaul S, Naz A, Mallela T, Maung PM, Khalaf IY, Kim S, Alrestom R, Gajera A, Alkealy H, Kansal D, Dhall S, Sathesha S, Weissman S, Fwelo P. Interaction between tumor stage and age on survival outcomes of patients with anaplastic thyroid cancer. *World J Exp Med* 2024; 14(3): 93869

URL: <https://www.wjgnet.com/2220-315x/full/v14/i3/93869.htm>

DOI: <https://dx.doi.org/10.5493/wjem.v14.i3.93869>

INTRODUCTION

Anaplastic thyroid cancer (ATC) is an aggressive and rare malignancy of the thyroid gland, accounting for approximately 1%-2% of all thyroid cancers[1]. It is characterized by rapid growth, early metastasis, and a dismal prognosis, with a median survival time of less than six months[2]. Over the past decade, significant advancements in our understanding of ATC's pathogenesis and treatment have emerged, shedding light on the critical factors influencing patient outcomes. The interaction between tumor stage and patient age are among these factors that have increased the attention of the medical community. This introduction aims to provide a comprehensive overview of the dynamic interplay between tumor stage and age and its impact on the survival outcomes of patients with ATC.

Thyroid cancer, in general, has been on the rise in recent years, with ATC representing the most aggressive form. Age has long been recognized as a crucial determinant in cancer development and progression, with distinct patterns observed across various cancer types. For ATC, it is imperative to explore how age influences the disease's presentation, progression, and survival outcomes, as it may offer invaluable insights into personalized treatment strategies. Several

studies have highlighted age as an independent prognostic factor for ATC patients, with older individuals often experiencing poorer survival rates[3]. Age-related disparities in tumor biology, immune response, and treatment tolerance contribute to these findings. Recent research suggests that age-related molecular alterations within ATC tumors may influence disease aggressiveness. These age-related genomic differences can affect tumor growth, response to therapy, and overall survival, further emphasizing the importance of considering age in the management of ATC[4].

Tumor stage at diagnosis remains a critical predictor of survival in ATC patients. The tumor, node, metastasis staging system provides valuable insights into disease severity[5]. However, it is essential to investigate how age modifies the prognostic significance of tumor stage in ATC. Age-related variations in clinical presentation and diagnostic delays are well-documented in ATC[6]. Older patients often present with more advanced disease due to less aggressive diagnostic workup, potentially confounding the association between tumor stage and age.

The management of ATC poses unique challenges in older patients, who may have comorbidities and reduced functional status. These factors can impact treatment choices and overall survival[7]. Over the past decade, novel treatment approaches, such as targeted therapies and immunotherapies, have shown promise in ATC[8]. However, the efficacy and safety of these treatments may vary with age, necessitating a nuanced assessment of their impact on survival outcomes. Combining surgery, radiation, and systemic therapies is often the cornerstone of ATC treatment. Understanding how age influences treatment response and tolerance is crucial in optimizing therapeutic strategies[9,10]. While age is typically considered a prognostic factor for various malignancies, thyroid cancer stands out due to its unique incorporation of age as a staging variable in the assessment of prognosis. Age can significantly impact treatment decision-making, with older patients often prioritizing quality of life over aggressive interventions. Shared decision-making between patients, families, and healthcare providers is paramount[11].

With the rapid evolution of precision medicine, ongoing research aims to identify age-specific biomarkers and therapeutic targets for ATC. Tailored treatment approaches may offer improved survival outcomes for both younger and older patients. International collaborations and data-sharing initiatives have facilitated the pooling of data from various centers, enabling the examination of large cohorts of ATC patients across different age groups[12].

MATERIALS AND METHODS

Study design

A retrospective cohort study was carried out on patients with ATC using data from the SEER research database. This database, managed by the United States National Cancer Institute, is renowned for its comprehensive cancer-related dataset. It encompasses 18 population-based cancer registries, collectively known as SEER 18, which compile data on cancer incidence, clinicopathological characteristics of patients, and survival rates. Covering approximately 28% of the United States population, the SEER 18 database is a significant and authoritative resource for cancer research[13].

Data selection

Inclusion criteria: We included all patients diagnosed with Hepatosplenic T-Cell Lymphoma between 2010 and 2017 in our cohort, identified from the SEER database using criteria related to primary site and histological type. Data for these patients were extracted from the SEER database using the specified International Classification of Diseases (ICD)-9, ICD-10, and/or ICD-O-3 codes.

Exclusion criteria: Patients with unknown age at diagnosis, race, or stage of ATC were excluded from the study.

Study variables

Main exposure: With the exception of the year of diagnosis, all variables within this cohort were utilized as primary predictors of prognosis.

Outcomes

Overall mortality was defined as patients who died from any cause by the end of the study being categorized as "yes", while those who did not were categorized as "no".

Cancer-specific mortality referred to patients who died from ATC at the end of the study being categorized as "yes", while those who died from other causes were classified as "no".

Survival months

Regarding overall mortality, survival time was computed from the date of diagnosis to either the date of death or the last follow-up date (December 31, 2017), as documented in the SEER registry.

Regarding cancer-specific mortality, survival time was determined from the date of diagnosis to either the date of death due to ATC or the last follow-up date, as documented in the SEER registry.

Sociodemographic and tumor characteristics

The following variables were extracted: Age at diagnosis, gender, race (White, Black, and others), ethnicity (Non-Hispanic and Hispanic), stage at diagnosis (localized, regional, and distant), geographic residential area, annual income, marital status, year of diagnosis, surgery, radiation and chemotherapy.

Statistical analysis

The Cox proportional hazards regression model relies on the assumption that hazard rates remain proportional over time. Variables with a significance level of < 0.1 in the univariate Cox regression model were included in the multivariate Cox proportional analysis to identify independent prognostic factors associated with overall mortality (OM) and cancer-specific mortality (CSM), where a hazard ratio (HR) > 1 indicates adverse prognostic factors. All tests were two-sided, with a confidence interval set at 95%, and a P value < 0.05 considered statistically significant. Statistical analyses were conducted using STATA 18.0 software.

RESULTS

We conducted our study with a cohort of ATC patients, comprising a total of 622 individuals. **Table 1** provides a comprehensive overview of the baseline characteristics of our study population. In our cohort, 58.84% were female, and 41.16% were male. Age distribution at diagnosis revealed that 20.58% fell within the 00-59 age group, 54.98% within the 60-79 age group, and 24.44% were aged 80 and above. Marital status varied, with 55.31% being married, 16.40% single, 6.75% divorced/separated, and 21.54% widowed. Tumor stage distribution indicated that a significant proportion (74.44%) of patients presented with distant metastasis, while 5.47% had localized tumors. In terms of race, the majority were non-Hispanic white (61.09%), followed by hispanic (18.01%), other (13.34%), and non-Hispanic black (7.56%). Living area analysis showed 58.68% in counties with a population of 1 million persons, 24.28% in areas with 250000 to 1 million persons, 5.14% in areas with 250000 persons, 6.59% in nonmetropolitan counties adjacent to a metropolitan area, and 5.31% in nonmetropolitan counties not adjacent to a metropolitan area. Income per year exhibited a diverse distribution, with 4.66% earning less than \$45000, 35.85% earning \$75000 and above, and varying percentages in the income brackets between. Treatment modalities varied, with 42.93% not receiving radiation, 55.14% not receiving chemotherapy, and 56.43% not undergoing surgery. The study spanned across different years of diagnosis, ranging from 12.06% in 2010 to 15.92% in 2017. These baseline characteristics provide a detailed snapshot of the demographic and clinicopathologic profile of our ATC patient cohort.

Table 2 illustrates the crude analysis of factors associated with all-cause mortality (OM) and CSM among United States patients diagnosed with ATC between 2010 and 2017. Age at diagnosis demonstrated significant associations, with higher OM and CRM observed in older age groups: 60-79 years (OM HR = 1.38, 95%CI: 1.10-1.74; CRM HR = 1.29, 95%CI: 1.02-1.64) and 80 + years (OM HR = 1.64, 95%CI: 1.24-2.16; CSM HR = 1.16, 95%CI: 1.19-2.08). Tumor stage also showed significant associations, with higher HRs for more advanced stages, particularly in tumors with local spread (OM HR = 2.12, 95%CI 1.22-3.66, $P < 0.01$; CSM HR = 2.07, 95%CI: 1.16-3.66, $P < 0.01$) and tumors with distant spread (OM HR = 3.24, 95%CI: 2.05-5.12; CSM HR = 3.25, 95%CI: 2.01-5.24). Furthermore, treatment modalities like radiation, chemotherapy, and surgery demonstrated significant associations with lower OM and CRM. Radiation (OM HR = 0.61, 95%CI: 0.50-0.74; CRM HR = 0.59, 95%CI: 0.49-0.72), chemotherapy (OM HR = 0.61, 95%CI: 0.50-0.73; CRM HR = 0.60, 95%CI: 0.49-0.72), and surgery (OM HR = 0.50, 95%CI: 0.41-0.59; CRM HR = 0.47, 95%CI: 0.39-0.58) were all significantly associated with lower OM and CRM. Associations marked with ^a $P < 0.05$ and ^b $P < 0.01$ indicate statistical significance at the respective levels. Confidence intervals are reported at the 95% level.

In **Table 3**, multivariate analyses, age did not demonstrate an adverse effect on mortality outcomes. However, the divorced/separated population exhibited a significantly lower risk of overall mortality (HR = 0.63, 95%CI: 0.42-0.94, $P < 0.05$) and cancer-specific mortality (HR = 0.61, 95%CI: 0.40-0.92, $P < 0.05$). Conversely, overall mortality was higher in tumors with direct extension only (HR = 6.26, 95%CI: 1.29-30.42, $P < 0.05$) and those with distant spread (HR = 5.73, 95%CI: 1.34-24.51, $P < 0.05$). Similarly, cancer-specific mortality was elevated in tumors with direct extension (HR = 5.05, 95%CI: 1.05-24.19, $P < 0.05$) and distant spread (HR = 4.57, 95%CI: 1.08-19.29, $P < 0.05$). However, mortality was not adversely affected by lymph node involvement. Moreover, patients who received radiation (HR = 0.66, 95%CI: 0.53-0.83, $P < 0.01$), chemotherapy (HR = 0.63, 95%CI: 0.50-0.79, $P < 0.01$), or surgery (HR = 0.53, 95%CI: 0.43-0.66, $P < 0.01$) had significantly lower risks of overall mortality. Similarly, cancer-specific mortality was reduced in patients who received radiation (HR = 0.64, 95%CI: 0.51-0.81, $P < 0.01$), chemotherapy (HR = 0.62, 95%CI: 0.50-0.78, $P < 0.01$), or surgery (HR = 0.51, 95%CI: 0.41-0.63, $P < 0.01$).

In **Table 4's** multivariate Cox proportional hazard regression analyses considering the interaction between tumor stage and age, several notable findings emerge regarding all-cause mortality (OM) and ATC-related mortality (CSM). In terms of specific interactions, there is no interaction between tumor stage and age significantly influencing mortality outcomes. However, it's important to note that the confidence intervals for many of these estimates are wide, indicating uncertainty in the estimates due to small sample sizes within some subgroups. Therefore, further investigation with larger datasets may be warranted to better understand the potential interactions between tumor stage and age on mortality outcomes in ATC patients.

DISCUSSION

In this large retrospective study using the SEER database, we found a female and non-Hispanic white predominance, most patients were diagnosed between 60 and 79 and at an advanced stage. There was almost an equal distribution between patients that received therapy and those that did not. Advanced age and advanced stage were associated with increased OM and CSM and all treatment modalities were associated with a lower OM and CSM, in the univariate

Table 1 Demographic and clinicopathologic characteristics of United States patients diagnosed with anaplastic thyroid cancer between 2010 and 2017

Characteristics	<i>n</i>	Percent
Gender		
Female	366	58.84
Male	256	41.16
Age at diagnosis, year old		
00-59	128	20.58
60-79	342	54.98
80 +	152	24.44
Marital status		
Married	344	55.31
Single	102	16.40
Divorced/separated	42	6.75
Widowed	134	21.54
Tumor stage		
Localized	34	5.47
Regional by direct extension only	47	7.56
Regional lymph nodes involved only	25	4.02
Regional by both direct extension and lymph node involvement	53	8.52
Distant	463	74.44
Race		
Non-Hispanic white	380	61.09
Non-Hispanic black	47	7.56
Hispanic	112	18.01
Other	83	13.34
Living area		
Counties in metropolitan areas of 1 million persons	365	58.68
Counties in metropolitan areas of 250000 to 1 million persons	151	24.28
Counties in metropolitan areas of 250000 persons	32	5.14
Nonmetropolitan counties adjacent to a metropolitan area	41	6.59
Nonmetropolitan counties not adjacent to a metropolitan area	33	5.31
Income per year		
\$ < \$45000	29	4.66
\$45000-54999	69	11.09
\$55000-64999	127	20.42
\$65000-74999	174	27.97
\$75000 +	223	35.85
Radiation		
No	267	42.93
Yes	355	57.07
Chemotherapy		
No	343	55.14

Yes	279	44.86
Surgery		
No	351	56.43
Yes	271	43.57
Year of diagnosis		
2010	75	12.06
2011	67	10.77
2012	64	10.29
2013	68	10.93
2014	74	11.90
2015	79	12.70
2016	96	15.43
2017	99	15.92

analysis. In the univariate analysis however, age did not affect mortality and interestingly, distant metastasis and local involvement of the thyroid cancer were associated with higher OM and CSM. All treatment modalities were again associated with lower OM and CSM. Furthermore, age and tumor stage did not interact with each other to affect mortality.

ATC is a rare cancer that tends to occur in older patients compared to differentiated thyroid cancers with a mean age of 65 years old at the time of diagnosis[14,15]. Our study mirrors the literature as most patients were diagnosed between 60 and 79. Previously available literature has highlighted a female predominance with up to 70% in the Kebebew series[14]. A similar trend was seen in the Nagaiah series[15]. Our study results are in adequacy with the current literature with a female involvement close to 60%. More than two thirds of our cohort had distant metastasis at the time of diagnosis. Distant metastasis at the time of diagnosis has been reported in up to 50% of patients in the available literature[16,17].

Most patients with ATC die within a few months, primarily because of local extension and airway obstruction[18]. Thus, tumor size plays an important role in the mortality of patients with ATC even without distant metastasis as shown in the literature[19,20]. A similar trend was observed in our cohort, patients with local invasion had the highest OM and CSM. Distant metastasis has also been shown to be a single predictor of poor outcome in the literature[21,22] with similar results in our cohort. Age has been shown to be an important independent factor of poor prognosis in several rare cancers [23-25]. Although the univariate analysis revealed a poor prognosis associated with advanced age, those results did not hold true in the multivariate analysis while considering covariates. This could be explained by the fact that most patients are diagnosed at advanced age[14,15], an observation that was made in our cohort as well, with most patients diagnosed between 60-79 years old followed by patients 80 years or older.

Several studies addressing cancer mortality have focused on the interaction of two or more independent prognostic factors. Some studies revealed a notable interaction while others did not find any[24,26]. In an effort to better understand factors associated with mortality of this malignancy with a very dismal prognosis, we conducted a study looking at the extent to which two independent prognostic factors would interact to affect mortality. We found that although age and advanced/Locally invasive disease individually affect prognosis, they do not interact to enhance mortality. This novel finding adds to the literature by unveiling an important area of this pathology that has not been studied yet. This finding suggests a novel area of study within ATC prognosis.

It has been demonstrated in the literature that married patients tend to have a lower mortality compared to their non married counterparts[23,26]. It was hypothesized that married patients may have stronger social support leading to a better outcome. However, a recent study on Primary cardiac sarcoma found a lower OM in widowed patients[27]. Interestingly, divorced patients had the best outcome in our cohort. A somehow similar trend was observed in anal canal squamous cell carcinoma where divorced patients had the second-best overall survival following married patients[28]. Our findings can be explained by a lower sample size of divorced patients in our cohort. Furthermore, most patients are diagnosed at an advanced stage and social support may not play a crucial role in mortality as seen in other cancers[23,27].

Although most patients are diagnosed at an advanced stage, all treatment modalities offered were associated with a lower OM and CSM. This finding is extremely important as early detection and management of this dismal cancer may significantly impact mortality. This data may assist treating oncologists in decision making for management of patients with this deadly malignancy. Patients with suspected locally invasive ATC should be promptly evaluated for resection as this may significantly impact their mortality. Historically, metastatic ATC is incurable with a median survival of 4.2 months. However, this data included a period from 1985 and 2009[29]. Our more recent and updated data offers a better prognostic picture. The study suggests a more favorable prognosis for ATC patients compared to historical data, likely due to advancements in targeted therapy and precision oncology. The findings may assist oncologists in decision-making regarding the management of ATC patients, emphasizing the importance of evaluating and managing based on cancer stage rather than age. Furthermore, available treatment modalities should be offered rather than end of life care given the improved mortality associated with our cohort. Overall, the study provides valuable insights into the demographic,

Table 2 Crude analysis of factors associated with all-cause mortality and cancer related mortality among United States patients diagnosed with anaplastic thyroid cancer between 2010 and 2017

Characteristics	Overall mortality	Cancer related mortality
	Crude proportional, HR (95%CI)	Crude proportional, HR (95%CI)
Gender		
Female	1 (Reference)	1 (Reference)
Male	0.97 (0.80-1.16)	0.96 (0.89-1.16)
Age at diagnosis, year old		
00-59	1 (Reference)	1 (Reference)
60-79	1.38 (1.10-1.74) ^b	1.29 (1.02-1.64) ^a
80 +	1.64 (1.24-2.16) ^b	1.16 (1.19-2.08) ^b
Marital status		
Married	1 (Reference)	1 (Reference)
Single	1.00 (0.77-1.30)	0.94 (0.71-1.23)
Divorced/separated	0.77 (0.54-1.11)	0.76 (0.52-1.11)
Widowed	1.23 (0.97-1.56)	1.22 (0.96-1.55)
Tumor stage		
Localized	1 (Reference)	1 (Reference)
Regional by direct extension only	2.12 (1.22-3.66) ^b	2.07 (1.16-3.66) ^a
Regional lymph nodes involved only	1.58 (0.81-3.09)	1.59 (0.79-3.20)
Regional by both direct extension and lymph node involvement	1.75 (1.02-3.00) ^a	1.82 (1.04-3.19) ^a
Distant	3.24 (2.05-5.12) ^b	3.25 (2.01-5.24) ^b
Race		
Non-Hispanic white	1 (Reference)	1 (Reference)
Non-Hispanic black	1.12 (0.79-1.59)	1.11 (0.78-1.59)
Hispanic	1.23 (0.96-1.58)	1.22 (0.94-1.57)
Other	1.30 (0.98-1.71)	1.27 (0.95-1.69)
Living area		
Counties in metropolitan areas of 1 million persons	1 (Reference)	1 (Reference)
Counties in metropolitan areas of 250000 to 1 million persons	1.11 (0.89-1.38)	1.11 (0.89-1.39)
Counties in metropolitan areas of 250000 persons	0.74 (0.46-1.18)	0.77 (0.47-1.24)
Nonmetropolitan counties adjacent to a metropolitan area	0.80 (0.55-1.14)	0.80 (0.55-1.16)
Nonmetropolitan counties not adjacent to a metropolitan area	1.41 (0.93-2.15)	1.49 (0.98-2.27)
Income per year		
\$ < \$45000	1 (Reference)	1 (Reference)
\$45000-54999	0.92 (0.55-1.54)	0.86 (0.51-1.45)
\$55000-64999	1.35 (0.85-2.17)	1.28 (0.80-2.06)
\$65000-74999	1.01 (0.64-1.60)	0.96 (0.60-1.52)
\$75000 +	0.90 (0.57-1.43)	0.85 (0.54-1.34)
Radiation		
No	1 (Reference)	1 (Reference)
Yes	0.61 (0.50-0.74) ^b	0.59 (0.49-0.72) ^b

Chemotherapy		
No	1 (Reference)	1 (Reference)
Yes	0.61(0.50-0.73) ^b	0.60(0.49-0.72) ^b
Surgery		
No	1 (Reference)	1 (Reference)
Yes	0.50 (0.41-0.59) ^b	0.47 (0.39-0.58) ^b

^a*P* < 0.05.

^b*P* < 0.01.

HR: Hazard ratio.

Table 3 Multivariate cox proportional hazard regression analyses of factors affecting all-cause mortality and cancer related mortality among United States patients diagnosed with anaplastic thyroid cancer between 2010 and 2017

Characteristics	Overall mortality	Cancer related mortality
	Adjusted proportional, HR (95%CI)	Adjusted proportional, HR (95%CI)
Gender		
Female	1 (Reference)	1 (Reference)
Male	1.11 (0.89-1.38)	1.09 (0.87-1.36)
Age at diagnosis, year old		
00-59	1 (Reference)	1 (Reference)
60-79	2.85 (0.61-13.43)	2.16 (0.46-10.18)
80 +	2.01 (0.40-10.18)	1.48 (0.29-7.60)
Marital status		
Married	1 (Reference)	1 (Reference)
Single	1.00 (0.75-1.34)	0.94 (0.69-1.26)
Divorced/separated	0.63 (0.42-0.94) ^a	0.61 (0.40-0.92) ^a
Widowed	1.03 (0.78-1.37)	1.03 (0.77-1.37)
Tumor stage		
Localized	1 (Reference)	1 (Reference)
Regional by direct extension only	6.26 (1.29-30.42) ^a	5.05 (1.05-24.19) ^a
Regional lymph nodes involved only	2.71 (0.42-17.49)	2.30 (0.36-14.68)
Regional by both direct extension and lymph node involvement	3.58 (0.74-17.31)	2.97 (0.62-14.15)
Distant	5.73 (1.34-24.51) ^a	4.57 (1.08-19.29) ^a
Race		
Non-Hispanic white	1 (Reference)	1 (Reference)
Non-Hispanic black	0.91 (0.62-1.35)	0.90 (0.60-1.34)
Hispanic	1.16 (0.90-1.51)	1.13 (0.87-1.49)
Other	1.14 (0.85-1.54)	1.12 (0.83-1.52)
Living area		
Counties in metropolitan areas of 1 million persons	1 (Reference)	1 (Reference)
Counties in metropolitan areas of 250000 to 1 million persons	1.26 (0.99-1.60)	1.26 (0.99-1.61)
Counties in metropolitan areas of 250000 persons	0.76 (0.46-1.27)	0.82 (0.49-1.38)

Nonmetropolitan counties adjacent to a metropolitan area	0.79 (0.50-1.26)	0.80 (0.50-1.29)
Nonmetropolitan counties not adjacent to a metropolitan area	1.19 (0.70-2.01)	1.25 (0.74-2.13)
Income per year		
\$ < \$45000	1 (Reference)	1 (Reference)
\$45000-54999	0.75 (0.43-1.31)	0.72 (0.41-1.26)
\$55000-64999	1.04 (0.59-1.82)	1.01 (0.57-1.77)
\$65000-74999	0.85 (0.48-1.51)	0.84 (0.47-1.50)
\$75000 +	0.74 (0.42-1.33)	0.71 (0.40-1.29)
Radiation		
No	1 (Reference)	1 (Reference)
Yes	0.66 (0.53-0.83) ^b	0.64 (0.51-0.81) ^b
Chemotherapy		
No	1 (Reference)	1 (Reference)
Yes	0.63 (0.50-0.79) ^b	0.62 (0.50-0.78) ^b
Surgery		
No	1 (Reference)	1 (Reference)
Yes	0.53 (0.43-0.66) ^b	0.51 (0.41-0.63) ^b

^a*P* < 0.05.

^b*P* < 0.01.

HR: Hazard ratio.

Table 4 Multivariate cox proportional hazard regression analyses of factors affecting all-cause mortality and anaplastic thyroid cancer related mortality among United States patients between 2010 and 2017 taking into account the interaction between tumor stage and age

Tumor stage and age (stage & age)	OM	CSM
I & 00-59	1	1
II & 00-59	1	1
II & 60-79	0.28 (0.06-1.62)	0.31 (0.05-1.85)
II & 80 +	0.32 (0.05-2.08)	0.43 (0.06-2.79)
III & 00-59	1	1
III & 60-79	0.43 (0.05-3.63)	0.44 (0.05-3.89)
III & 80 +	0.70 (0.08-6.13)	0.91 (0.10-8.07)
IV & 00-59	1	1
IV & 60-79	0.53 (0.09-2.99)	0.65 (0.11-3.65)
IV & 80 +	0.52 (0.07-3.90)	0.70 (0.09-5.29)
V & 00-59	1	1
V & 60-79	0.44 (0.09-2.09)	0.54 (0.11-2.58)
V & 80 +	0.70 (0.13-3.66)	0.87 (0.16-4.63)

CSM: Cancer specific mortality; OM: Overall mortality.

clinical, and prognostic factors of ATC, highlighting the importance of early detection, prompt management, and the potential impact of treatment modalities on patient outcomes.

Certain limitations must be considered in the interpretation of the results of this study. The information available for chemotherapy did not specify if this treatment was given as neoadjuvant or adjuvant. Furthermore, the SEER database, the largest cancer database in the United States that is publicly available, does not provide information on comorbidities.

CONCLUSION

In conclusion, our ATC mortality study from 2010 to 2017 reveals notable trends: Heightened risk in the 80 + age group, with distant metastasis and residing in nonmetropolitan areas without adjacency to a metropolitan center. A distinctive finding is the protective effect among divorced/separated individuals. This aligns with existing literature, emphasizing age and tumor stage as crucial influencers in ATC outcomes. From a clinical perspective, recognizing the vulnerability of the elderly and the impact of marital status informs targeted interventions. Regional disparities in nonmetropolitan areas highlight the need for focused healthcare strategies. Future research should probe mechanisms behind the protective effect among divorced/separated individuals and address healthcare disparities in nonmetropolitan areas. Our study provides a foundation for understanding ATC mortality factors, guiding the development of personalized healthcare strategies.

FOOTNOTES

Author contributions: Bangolo A and Fwelo P designed the research study; Bangolo A, Auda A, Bukasa-Kakamba J, Bhakta N, Dey S, Lilhori A, Reddy G, Alqinai B, Sidiqei A, Sekhon I, Khatiasvili B, Abbas I, Kunnel S, Jarri A, Martinez E, Daoud D, Gupta I, Gompa H, Pender S, Aljaberi D performed the research; Bangolo A, Aljanaahi H, Kunnel SS, Xiao Y, Jung Y, Nagpaul S, Naz A, Mallela T, Maung PM, Khalaf IY, Kim S, Alrestom R, Gajera A, Alkealy H, Kansal D, Dhall S, Satheesha S, Weissman S analyzed the data and wrote the manuscript; All authors have read and approved the final manuscript.

Conflict-of-interest statement: No potential conflict of interest was reported by the authors.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country of origin: United States

ORCID number: Ayrton I Bangolo 0000-0002-2133-2480.

S-Editor: Liu JH

L-Editor: A

P-Editor: Wang WB

REFERENCES

- Peterson GW, Browe MA, Durke EM, Epps TH 3rd. Flexible SIS/HKUST-1 Mixed Matrix Composites as Protective Barriers against Chemical Warfare Agent Simulants. *ACS Appl Mater Interfaces* 2018; **10**: 43080-43087 [PMID: 30426748 DOI: 10.1021/acsami.8b16227]
- Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, Kebebew E, Lee NY, Nikiforov YE, Rosenthal MS, Shah MH, Shaha AR, Tuttle RM; American Thyroid Association Anaplastic Thyroid Cancer Guidelines Taskforce. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. *Thyroid* 2012; **22**: 1104-1139 [PMID: 23130564 DOI: 10.1089/thy.2012.0302]
- Sugitani I, Miyachi A, Sugino K, Okamoto T, Yoshida A, Suzuki S. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. *World J Surg* 2012; **36**: 1247-1254 [PMID: 22311136 DOI: 10.1007/s00268-012-1437-z]
- Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. *Cell* 2014; **159**: 676-690 [PMID: 25417114 DOI: 10.1016/j.cell.2014.09.050]
- Tuttle RM, Haugen B, Perrier ND. Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why? *Thyroid* 2017; **27**: 751-756 [PMID: 28463585 DOI: 10.1089/thy.2017.0102]
- Kong N, Xu Q, Zhang Z, Cui A, Tan S, Bai N. Age Influences the Prognosis of Anaplastic Thyroid Cancer Patients. *Front Endocrinol (Lausanne)* 2021; **12**: 704596 [PMID: 34385977 DOI: 10.3389/fendo.2021.704596]
- Saini S, Tulla K, Maker AV, Burman KD, Prabhakar BS. Therapeutic advances in anaplastic thyroid cancer: a current perspective. *Mol Cancer* 2018; **17**: 154 [PMID: 30352606 DOI: 10.1186/s12943-018-0903-0]
- Pavlidis ET, Galanis IN, Pavlidis TE. Update on current diagnosis and management of anaplastic thyroid carcinoma. *World J Clin Oncol* 2023; **14**: 570-583 [PMID: 38179406 DOI: 10.5306/wjco.v14.i12.570]
- De Leo S, Trevisan M, Fugazzola L. Recent advances in the management of anaplastic thyroid cancer. *Thyroid Res* 2020; **13**: 17 [PMID: 33292371 DOI: 10.1186/s13044-020-00091-w]
- Houlihan OA, Moore R, Jamaluddin MF, Sharifah A, Redmond HP, O'Reilly S, Feeley L, Sheahan P, Rock K. Anaplastic thyroid cancer: outcomes of trimodal therapy. *Rep Pract Oncol Radiother* 2021; **26**: 416-422 [PMID: 34277095 DOI: 10.5603/RPOR.a2021.0042]
- Sio TT, Chang K, Jayakrishnan R, Wu D, Politi M, Malacarne D, Saletnik J, Chung M. Patient age is related to decision-making, treatment selection, and perceived quality of life in breast cancer survivors. *World J Surg Oncol* 2014; **12**: 230 [PMID: 25052797 DOI: 10.1186/1477-7819-12-230]
- Cabanillas ME, Zafereo M, Gunn GB, Ferrarotto R. Anaplastic Thyroid Carcinoma: Treatment in the Age of Molecular Targeted Therapy. *J Oncol Pract* 2016; **12**: 511-518 [PMID: 27288464 DOI: 10.1200/JOP.2016.012013]

- 13 **Duggan MA**, Anderson WF, Altekruse S, Penberthy L, Sherman ME. The Surveillance, Epidemiology, and End Results (SEER) Program and Pathology: Toward Strengthening the Critical Relationship. *Am J Surg Pathol* 2016; **40**: e94-e102 [PMID: 27740970 DOI: 10.1097/PAS.0000000000000749]
- 14 **Kebebew E**, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. *Cancer* 2005; **103**: 1330-1335 [PMID: 15739211 DOI: 10.1002/cncr.20936]
- 15 **Nagaiah G**, Hossain A, Mooney CJ, Parmentier J, Remick SC. Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. *J Oncol* 2011; **2011**: 542358 [PMID: 21772843 DOI: 10.1155/2011/542358]
- 16 **Nel CJ**, van Heerden JA, Goellner JR, Gharib H, McConahey WM, Taylor WF, Grant CS. Anaplastic carcinoma of the thyroid: a clinicopathologic study of 82 cases. *Mayo Clin Proc* 1985; **60**: 51-58 [PMID: 3965822 DOI: 10.1016/s0025-6196(12)65285-9]
- 17 **Carcangiu ML**, Steeper T, Zampi G, Rosai J. Anaplastic thyroid carcinoma. A study of 70 cases. *Am J Clin Pathol* 1985; **83**: 135-158 [PMID: 2578727 DOI: 10.1093/ajcp/83.2.135]
- 18 **Pasiaka JL**. Anaplastic thyroid cancer. *Curr Opin Oncol* 2003; **15**: 78-83 [PMID: 12490766 DOI: 10.1097/00001622-200301000-00012]
- 19 **Molina PE**, Simon L, Amedee AM, Welsh DA, Ferguson TF. Corrigendum: Impact of Alcohol on HIV Disease Pathogenesis, Comorbidities and Aging: Integrating Preclinical and Clinical Findings. *Alcohol Alcohol* 2018; **53**: 636 [PMID: 29850892 DOI: 10.1093/alcalc/agy043]
- 20 **Tan RK**, Finley RK 3rd, Driscoll D, Bakamjian V, Hicks WL Jr, Shedd DP. Anaplastic carcinoma of the thyroid: a 24-year experience. *Head Neck* 1995; **17**: 41-7; discussion 47 [PMID: 7883548 DOI: 10.1002/hed.2880170109]
- 21 **Marcello-Machado RM**, Faot F, Schuster AJ, Bielemann AM, Chagas Júnior OL, Del Bel Cury AA. How does mandibular bone atrophy influence the masticatory function, OHRQoL and satisfaction in overdenture wearers? Clinical results until 1-year post-loading. *J Oral Rehabil* 2017; **44**: 850-859 [PMID: 28741684 DOI: 10.1111/joor.12546]
- 22 **Venkatesh YS**, Ordonez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NA. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. *Cancer* 1990; **66**: 321-330 [PMID: 1695118 DOI: 10.1002/1097-0142(19900715)66:2<321::aid-cncr2820660221>3.0.co;2-a]
- 23 **Bangolo A**, Fwelo P, Al-Qatish T, Bukasa-Kakamba J, Lee T, Cayago AG, Potiguara S, Nagesh VK, Kwall J, Ahmed R, Asjad Abbas M, Nursjamsi N, Lee SH, Meti S, Arana GV, Joseph CA, Mohamed A, Alencar A, Hassan HG, Aryal P, Javed A, Kalinin M, Lawal G, Khalaf IY, Mathew M, Karamthoti P, Gupta B, Weissman S. Outcomes of Patients with Gastrointestinal Stromal Tumors in the Past Decade. *Med Sci (Basel)* 2023; **11** [PMID: 37755158 DOI: 10.3390/medsci11030054]
- 24 **Bangolo A**, Fwelo P, Sagireddy S, Shah H, Trivedi C, Bukasa-Kakamba J, Patel R, Bharane L, Randhawa MK, Nagesh VK, Dey S, Terefe H, Kaur G, Dinko N, Emiroglu FL, Mohamed A, Fallorina MA, Kosoy D, Waqar D, Shenoy A, Ahmed K, Nanavati A, Singh A, Willie A, Gonzalez DMC, Mukherjee D, Sajja J, Proverbs-Singh T, Elias S, Weissman S. Interaction between Age and Primary Site on Survival Outcomes in Primary GI Melanoma over the Past Decade. *Med Sci (Basel)* 2023; **11** [PMID: 37218984 DOI: 10.3390/medsci11020032]
- 25 **Ishitsuka K**. Prognostic indices for peripheral T-cell lymphoma - not otherwise specified and adult T-cell leukemia/lymphoma: From past to future. *J Clin Exp Hematop* 2023; **63**: 1-11 [PMID: 36709976 DOI: 10.3960/jslrt.22034]
- 26 **Bangolo AI**, Fwelo P, Trivedi C, Sagireddy S, Aljanaahi H, Auda A, Mohamed M, Onyeka S, Fisher M, Thapa J, Tabucanon EJ, Georgiev L, Wishart A, Kumari S, Erikson C, Bangura M, Paddy O, Madhukar R, Gomez EL, Rathod J, Naria M, Hajal B, Awadhalla M, Siegel D, Parmar H, Biran N, Vesole DH, Phull P, Weissman S. Interaction between age and gender on survival outcomes in extramedullary multiple myeloma over the past two decades. *World J Clin Oncol* 2023; **14**: 179-189 [PMID: 37124133 DOI: 10.5306/wjco.v14.i4.179]
- 27 **Bangolo A**, Fwelo P, Iyer KM, Klinger S, Tavares L, Dey S, Chacko AA, Hein M, Gudena S, Lawal G, Sivasubramanian BP, Rimba Z, Hirpara K, Merajunnissa M, Veliginti S, Arana G, Sathyarajan DT, Singh S, Shetty T, Bhardwaj K, Hashemy S, Duran RL, Kim SH, Hipolito CM, Yoon K, Patel V, Alshimari A, Inban P, Yasmeen S, Devanaboyina K, Kumar G, Preet S, Akhtar M, Abdi A, Nalajala N, Rizvi SFM, Gupta B, Weissman S. Primary Cardiac Sarcoma: Clinical Characteristics and Prognostic Factors over the Past 2 Decades. *Diseases* 2023; **11** [PMID: 37218887 DOI: 10.3390/diseases11020074]
- 28 **Yang T**, Xiao H, Sun F, Guo X. Impact of marital status at diagnosis on the survival of patients with anal canal squamous cell carcinoma: a propensity score-matched analysis. *Int J Colorectal Dis* 2022; **37**: 2335-2345 [PMID: 36241859 DOI: 10.1007/s00384-022-04264-x]
- 29 **Ito K**, Hanamura T, Murayama K, Okada T, Watanabe T, Harada M, Ito T, Koyama H, Kanai T, Maeno K, Mochizuki Y, Amano J. Multimodality therapeutic outcomes in anaplastic thyroid carcinoma: improved survival in subgroups of patients with localized primary tumors. *Head Neck* 2012; **34**: 230-237 [PMID: 21500309 DOI: 10.1002/hed.21721]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: office@baishideng.com
Help Desk: <https://www.f6publishing.com/helpdesk>
<https://www.wjgnet.com>

